MA55560A - Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer - Google Patents

Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer

Info

Publication number
MA55560A
MA55560A MA055560A MA55560A MA55560A MA 55560 A MA55560 A MA 55560A MA 055560 A MA055560 A MA 055560A MA 55560 A MA55560 A MA 55560A MA 55560 A MA55560 A MA 55560A
Authority
MA
Morocco
Prior art keywords
cancer
treatment
amide derivatives
heteroaromatic amide
heteroaromatic
Prior art date
Application number
MA055560A
Other languages
English (en)
Inventor
Liming Bao
Chaole Chen
John J Talley
Liangliang Xu
Xuan Yang
Chaochun Zhang
Chenggang Zhu
Original Assignee
Shenzhen Forward Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Forward Pharmaceuticals Co Ltd filed Critical Shenzhen Forward Pharmaceuticals Co Ltd
Publication of MA55560A publication Critical patent/MA55560A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA055560A 2019-03-29 2020-03-30 Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer MA55560A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910252714 2019-03-29
CN201910616031 2019-07-09

Publications (1)

Publication Number Publication Date
MA55560A true MA55560A (fr) 2022-02-09

Family

ID=72664733

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055560A MA55560A (fr) 2019-03-29 2020-03-30 Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer

Country Status (8)

Country Link
US (1) US12258344B2 (fr)
EP (1) EP3950686A4 (fr)
JP (1) JP7337951B2 (fr)
KR (1) KR102728940B1 (fr)
CN (3) CN111747950B (fr)
AU (1) AU2020255100C1 (fr)
MA (1) MA55560A (fr)
WO (1) WO2020200158A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202128670A (zh) * 2019-11-26 2021-08-01 大陸商上海翰森生物醫藥科技有限公司 含氮多環類衍生物抑制劑、其製備方法和應用
US20230234941A1 (en) * 2020-06-23 2023-07-27 Shenzhen Forward Pharmaceuticals Co., Limited. Salts of Compound and Pharmaceutical Compositions Containing the Same
WO2022033455A1 (fr) * 2020-08-13 2022-02-17 上海和誉生物医药科技有限公司 Dérivé de triazine ayant une activité inhibitrice d'egfr, son procédé de préparation et son utilisation
CN115867539B (zh) * 2020-12-02 2025-07-22 上海和誉生物医药科技有限公司 2,3-二氢-1H-吡咯并[3,2-b]吡啶衍生物、其制备方法和应用
US20240226101A1 (en) * 2021-04-30 2024-07-11 Suzhou Puhe BioPharma Co., Ltd. Pyrimidinylaminobenzenes for lung cancer treatment
WO2022237825A1 (fr) * 2021-05-13 2022-11-17 上海和誉生物医药科技有限公司 Dérivé d'azaaryle ayant une activité inhibitrice de l'egfr, son procédé de préparation et son utilisation
CN117858872A (zh) * 2021-06-22 2024-04-09 缆图药品公司 用于治疗癌症的杂环egfr抑制剂
WO2022271613A1 (fr) * 2021-06-22 2022-12-29 Blueprint Medicines Corporation Inhibiteurs hétérocycliques d'egfr destinés à être utilisés dans le traitement du cancer
US20240299387A1 (en) * 2021-06-22 2024-09-12 Blueprint Medicines Corporation Heterocyclic egfr inhibitors for use in the treatment of cancer
CN117940424A (zh) * 2021-06-22 2024-04-26 缆图药品公司 Egfr抑制剂
CN113387935B (zh) * 2021-07-23 2022-06-10 苏州雅深智慧科技有限公司 抑制三突变表皮生长因子受体酪氨酸激酶的化合物及用途
WO2024094064A1 (fr) * 2022-11-02 2024-05-10 Suzhou Puhe Biopharma Co., Ltd Pyrimidinylaminobenzènes pour le traitement du cancer du poumon avec métastase distante
WO2025108313A1 (fr) * 2023-11-21 2025-05-30 深圳福沃药业有限公司 Composition pharmaceutique comprenant un inhibiteur d'egfr

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368367A1 (fr) * 1984-12-21 1990-05-16 Biogen, Inc. Purification, production et utilisation de facteurs de nécrose de tumeur
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
PT1154774E (pt) 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
US9908884B2 (en) * 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
MX342164B (es) * 2010-06-23 2016-09-19 Hanmi Science Co Ltd Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa.
EP4119551A1 (fr) 2011-07-27 2023-01-18 Astrazeneca AB Composés de 2-(anilino 2,4,5-substitué)pyrimidine
JO3300B1 (ar) * 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
EP3170825B1 (fr) 2012-08-06 2019-04-10 ACEA Biosciences Inc. Pyrrolopyridines utiles en tant qu'inhibiteurs de protéines kinases
EP2964638B1 (fr) 2013-03-06 2017-08-09 Astrazeneca AB Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
CN104860941B (zh) * 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
CA2943220C (fr) 2014-03-20 2024-01-16 Capella Therapeutics, Inc. Derives de benzimidazole comme inhibiteurs de tyrosine kinase de famille erbb pour le traitement du cancer
WO2015188777A1 (fr) 2014-06-12 2015-12-17 Shanghai Fochon Pharmaceutical Co Ltd Inhibiteurs particuliers de protéines kinases
WO2015188747A1 (fr) * 2014-06-12 2015-12-17 南京圣和药业股份有限公司 Composé de triazine substitué par phényle servant d'inhibiteur de l'egfr et ses applications
EP3778584A1 (fr) * 2014-06-19 2021-02-17 ARIAD Pharmaceuticals, Inc. Procédé de préparation de dérivés de 2-chloro-4-hétéroaryl-pyridimidines
CN105254615B (zh) * 2014-07-11 2017-02-22 杭州华东医药集团新药研究院有限公司 苯胺嘧啶衍生物及其在制备抗恶性肿瘤药物中的用途
CN105315259B (zh) * 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
CN105461695B (zh) * 2014-09-29 2018-03-27 齐鲁制药有限公司 嘧啶或三嗪衍生物及其制备方法和用途
WO2016054987A1 (fr) 2014-10-11 2016-04-14 上海翰森生物医药科技有限公司 Inhibiteur d'egfr, et préparation et application associées
HUE054848T2 (hu) * 2014-10-13 2021-09-28 Yuhan Corp Vegyületek és készítmények EGFR mutáns kináz aktivitás módosítására
CN105085489B (zh) * 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
WO2016105525A2 (fr) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Nouvelles pyrimidines en tant qu'inhibiteurs d'egfr et procédés de traitement de troubles
CN106117185B (zh) 2015-08-31 2017-11-07 广州必贝特医药技术有限公司 2,4‑二含氮基团取代嘧啶类化合物及其制备方法和应用
WO2017035753A1 (fr) 2015-08-31 2017-03-09 无锡双良生物科技有限公司 2-arylamino pyridine, dérivé de pyridine ou de triazine, leur procédé de préparation et leur utilisation
RU2606949C9 (ru) * 2015-11-19 2018-03-14 ЗАО "Р-Фарм" Замещенные N-{ 3-[4-(1-метил-1Н-индол-3-ил)пиримидин-2-иламино]-4-метоксифенил} -амиды в качестве модуляторов EGFR, предназначенные для лечения рака
CN106749193B (zh) * 2015-11-23 2020-11-20 南京圣和药业股份有限公司 吲唑取代的表皮生长因子受体抑制剂及其应用
CN106928200A (zh) * 2015-12-30 2017-07-07 湖南福沃药业有限公司 用于治疗癌症的三嗪衍生物
CN106928150B (zh) * 2015-12-31 2020-07-31 恩瑞生物医药科技（上海）有限公司 丙烯酰胺苯胺衍生物及其药学上的应用
CN107163026B (zh) * 2016-03-07 2019-07-02 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物的盐及其制备方法和应用
CN106279160B (zh) * 2016-03-18 2017-09-26 海南越康生物医药有限公司 N‑苯基‑2‑氨基嘧啶类化合物制备方法和用途
CN112645932B (zh) 2016-03-22 2022-01-14 江苏豪森药业集团有限公司 Egfr抑制剂游离碱或其酸式盐的多晶型、其制备方法和应用
EP3492462B1 (fr) 2016-07-26 2023-08-30 Shenzhen TargetRx, Inc. Composé amino pyrimidine pour inhiber l'activité de la protéine tyrosine kinase
CN108864079B (zh) * 2017-05-15 2021-04-09 深圳福沃药业有限公司 一种三嗪化合物及其药学上可接受的盐
CN111093645A (zh) * 2017-07-05 2020-05-01 Cs制药技术有限公司 Egfr酪氨酸激酶的临床上重要的突变体的选择性抑制剂
CN107266437B (zh) * 2017-07-19 2019-08-30 海南越康生物医药有限公司 N-苯基-2-氨基嘧啶类化合物的晶型、盐型及其制备方法
JP6985764B2 (ja) * 2017-08-30 2021-12-22 深▲チェン▼市塔吉瑞生物医薬有限公司Shenzhen TargetRx, Inc. アミノピリミジン系化合物、この化合物を含む組成物およびそれらの使用
CN107935995A (zh) * 2017-11-28 2018-04-20 中山大学 一种新型2‑苯胺基嘧啶衍生物及其在制备抗肿瘤药物中的应用
US11266624B2 (en) * 2018-04-03 2022-03-08 Texas Tech University System CRM1 inhibitors reduce primary and acquired resistance of EGFR inhibitors in lung cancer cells
WO2019197605A2 (fr) * 2018-04-12 2019-10-17 Umc Utrecht Holding B.V. Associations médicamenteuses à utiliser dans le traitement du cancer à mutation de ras
WO2020043757A1 (fr) * 2018-08-29 2020-03-05 Universite Nice Sophia Antipolis Prédiction de la réponse au traitement d'une molécule anti-egfr d'un sujet souffrant d'un cancer du rein
CN109761960B (zh) 2019-02-25 2021-08-31 江苏豪森药业集团有限公司 抗耐药抗肿瘤egfr抑制剂的制备方法

Also Published As

Publication number Publication date
WO2020200158A1 (fr) 2020-10-08
US12258344B2 (en) 2025-03-25
EP3950686A4 (fr) 2022-09-07
AU2020255100B2 (en) 2022-11-24
AU2020255100A1 (en) 2021-11-25
CN111747950A (zh) 2020-10-09
AU2020255100C1 (en) 2023-02-23
JP7337951B2 (ja) 2023-09-04
AU2020255100A8 (en) 2021-12-02
JP2022529616A (ja) 2022-06-23
US20220177473A1 (en) 2022-06-09
KR20210144853A (ko) 2021-11-30
KR102728940B1 (ko) 2024-11-13
CN111747950B (zh) 2024-01-23
CN111747931A (zh) 2020-10-09
CN113727982A (zh) 2021-11-30
EP3950686A1 (fr) 2022-02-09

Similar Documents

Publication Publication Date Title
MA55560A (fr) Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer
MA56508A (fr) Inhibiteur d'egfr pour le traitement du cancer
CY1124257T1 (el) N-[4-ΦΘOPO-5-[[(2S,4S)-2-MEΘYΛO-4-[(5-MEΘYΛO-1,2,4-ΟΞAΔIAZOΛ-3-YΛO)MEΘOΞY]-l-ΠΙΠΕΡΙΔΥΛΟ]ΜΕΘΥΛΟ]ΘΕΙΑΖΟΛ-2-ΥΛΟ]ΑΚΕΤΑΜΙΔΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ OGA
EP3641829A4 (fr) Promédicament d'interféron pour le traitement du cancer
IL281809A (en) Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
EP3762407A4 (fr) Méthodes et compositions destinées au traitement du cancer à l'aide de peptides à affinité mec liés à des cytokines
EP3790867A4 (fr) Inhibiteurs de kdm1a pour le traitement d'une maladie
MA53562A (fr) Polythérapie destinée au traitement d'une maladie hépatique
EP3405183A4 (fr) Dérivés d'adamatane pour le traitement d'une infection à filovirus
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
MA49141A (fr) Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau
EP3773632A4 (fr) Méthodes de traitement de glioblastomes exprimant l'egfrviii
EP3648769A4 (fr) N-acyl amides dérivés du microbiote humain pour le traitement d'une maladie humaine
EP3672587A4 (fr) Compositions pharmaceutiques destinées au traitement d'affections ophtalmiques
EP3947460A4 (fr) Agents multispécifiques pour le traitement du cancer
EP3911313A4 (fr) Composés thiényl-aniline destinés au traitement d'affections de la peau
EP4021858A4 (fr) Traitement d'azoles
EP3347010A4 (fr) Synthèse et composition d'agents thérapeutiques photodynamiques pour le traitement ciblé du cancer
IL309468A (en) Biomarkers for alzheimer's disease treatment
EP3773221A4 (fr) Traitement pour l'hydrocéphalie
MA54522A (fr) Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire
MA55084A (fr) Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau
EP3752198A4 (fr) Émetteur d'électrons thérapeutiques pour le traitement du cancer
EP3730144A4 (fr) Agent pour le traitement d'une maladie du système nerveux
EP3883567A4 (fr) Composés naphthyridinone-aniline destinés au traitement d'affections de la peau